What is the mechanism of action of cimepilimab? What kind of immunotherapy is it?

Cemiplimab is an anti-PD-1 monoclonal antibody that belongs to the immune checkpoint inhibitor class. It exerts anti-tumor effects by inhibiting the binding of PD-1 (programmed death receptor -1) and its ligand PD-L1, thereby enhancing the recognition and attack of tumor cells by the body's immune system. On the surface of tumor cells, when PD-L1 binds to the PD-1 receptor on the surface of T cells, it will lead to the suppression of T cells and reduce the immune response. This mechanism allows tumor cells to evade surveillance and clearance by the immune system.

Cimepilimab restores the activity of T cells by blocking the binding of PD-1 receptors to PD-L1, allowing them to recognize and attack tumor cells. This effect not only enhances the natural immune response in the body, but also promotes the generation of tumor-specific immune responses, thereby effectively inhibiting the growth and spread of tumors. Cimepilimab is one of the important means of modern tumor immunotherapy by enhancing the immune function of T cells.

Cimepilimab is a type of "immune checkpoint inhibition therapy", which enhances the immune system's attack on tumors by removing the immune system's inhibitory effect on tumors. Immune checkpoint inhibitor drugs, such as cimepilimab, block the negative signals between tumor cells and immune cells by inhibiting PD-1 or its ligand PD-L1, thereby activating the anti-tumor effect of T cells. Unlike traditional chemotherapy drugs and radiotherapy, immune checkpoint inhibitors fight tumors by activating the own immune system and are highly specific and long-lasting.

The success of immunotherapy in tumor treatment has brought new breakthroughs in cancer treatment, and the mechanism of action of cimipilimab is part of this new immunotherapy strategy. By removing the inhibitory effect of immune checkpoints, cimepilimab not only improves the patient's immune response, but also reduces the side effects of traditional treatments to a certain extent. Therefore, cimepilimab is widely used in the treatment of various types of tumors, including advanced skin cancer, non-small cell lung cancer, etc.

Reference materials:https://www.libtayohcp.com/